Skip to main content

Table 2 Conventional and speckle-tracking echocardiographic parameters of normal control and diabetic patients before and after 3 months of telmisartan treatment

From: Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor δ (PPARδ): from bedside to bench

  Normal control (n = 10) Baseline (n = 15) After telmisartan (n = 15) p value
LVMI (g/m2) 83.3 ± 29.1 84.5 ± 29.8 85.1 ± 30.2 0.63
LVIDd (cm) 4.2 ± 0.8 4.1 ± 0.7 4.1 ± 1.4 0.52
LVEF (%) 70.5 ± 6.4 68.1 ± 4.5 69.3 ± 15.7 0.38
E (cm/s) 76.5 ± 18.3 79.5 ± 12.3 82.7 ± 18.3 0.72
E/A 1.0 ± 0.3 1.0 ± 0.2 0.9 ± 0.6 0.06
e′ (cm/s) 10.3 ± 2.8 8.2 ± 1.8 9.3 ± 2.7 0.01
IVRT (ms) 94.7 ± 23 96.6 ± 13.1 90.7 ± 21.5 0.06
DT (ms) 200.5 ± 58.6 184.1 ± 52.2 198.4 ± 43.7 0.93
MPI 0.4 ± 0.2 0.5 ± 0.1 0.5 ± 0.1 0.35
GLS (%) −20.2 ± 6.7 −16.4 ± 5.2 −18.1 ± 6.2 0.03
GCS (%) −22.2 ± 7.8 −14.7 ± 8.6 −20.8 ± 6.8 0.01
  1. Data are expressed as mean ± standard deviation. Italics indicate significance
  2. LVMI left ventricular mass index, LVIDd left ventricular interior dimension at end diastole, LVEF left ventricular ejection fraction, IVRT isovolumic relaxation time, DT deceleration time, E/A transmitral valve E to A velocity ratio, E/eʹ mitral early filling velocity to early diastolic mitral annular velocity ratio, MPI myocardial performance index, GLS peak systolic global longitudinal strain, GCS peak systolic global circumferential strain